Blank Bio Funding Round

5/20/2026

Venture Equity

$7,200,000

Seed

The company intends to use the funds to support continued model development, expanded collaborations with pharmaceutical and diagnostic companies, and new long-read RNA-seq datasets to support applications in biomarkers, clinical trial design, and diagnostics.

Private & Independent

Biopharmaceutical

535 Mission St, 14th Floor (c/o WeWork)
San Francisco, CA 94105
USA

Undisclosed

Billion-dollar clinical trial decisions are still made with limited insight into each patient's underlying biology, leading to expensive failures. Today, we often rely on crude proxies of biology and the same biomarkers to answer critical questions like which patients will respond to a therapy and how their disease will progress. Blank Bio is an applied AI research lab building models that help make sense of that data. We train RNA foundation models to learn patterns linked to disease progression and treatment response. Our goal is to help pharma companies make better clinical development decisions, design smaller and more efficient trials, and increase the odds that promising therapies succeed.